Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026

COMPASS Pathways plc

Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.
Q4 2025 net loss $93.9M ($1.00/share), vs $43.3M in Q4 2024.
COMP360 in TRD: highly statistically significant Phase 3 results; FDA meeting to confirm rolling NDA submission, expected completion in Q4 2026.
Phase 2b/3 trial in PTSD initiated after FDA acceptance of IND.
Cash $149.6M at Dec 31, 2025; $150M Feb financing plus $200M warrant exercise extends cash runway into 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COMPASS Pathways plc reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001816590-26-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.